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Objective: Recombinant activated factor VII (rFVIIa) is a novel hemostatic 
agent originally developed to treat hemophilia patients who had developed 
inhibitors with bleeding. Its role in treating uncontrolled bleeding in patients 
without pre-existing coagulation abnormalities has not been well established. 
We herein report our experiences with its use in non-hemophilic patients.
Patients and Methods: Four patients, aged 33 to 94 years, with differ-
ent underlying diseases were treated with rFVIIa for uncontrolled, life-
threatening hemorrhage. rFVIIa was initially administered by intravenous 
bolus injection at 80–100 μg/kg. Doses were adjusted according to clinical 
response.
Results: Clinical response with significant hemostasis was evident in three 
patients after initial treatment. One patient was unresponsive to rFVIIa 
treatment and died of uncontrolled bleeding. Of those who achieved ini-
tial hemostasis, two died of their underlying diseases. One had recurrent 
bleeding controlled by subsequent multiple doses of rFVIIa, but she died of 
acute myocardial infarction, a thromboembolic complication that probably 
arose from the use of rFVIIa.
Conclusion: Our results suggest that rFVIIa could play a role in the man-
agement of bleeding other than congenital coagulation disorder. However, 
clinical hemostatic effects that do not translate into a survival benefit 
require further study, especially with regard to appropriate timing for clinical 
use. Its potential risk, especially that of thromboembolism when treating 
bleeding in elderly patients, warrants further investigation. [Tzu Chi Med J 
2007;19(4):220–225]
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Table 1 — Patient characteristics and treatment outcomes from rFVIIa





 Hemostatic  Cause of
   disorders  (μg/kg)  response death
1 84 F MDS with GI tract, oral 90, 45 2 Effective Pneumonia
    thrombocytopenia,  mucosa, venous
    pneumonia  puncture sites
2 33 M CML s/p BMT, Lung 80, 100 2 Partially effective CMV pneumonia
    CMV pneumonia
3 94 F CRF, GI bleeding GI tract 100 7 Partially effective AMI
4 46 M Oral cancer Small intestine 85 2 Ineffective Intractable
         bleeding
MDS = myelodysplastic syndrome; CML = chronic myeloid leukemia; BMT = bone marrow transplantation; CMV = cytomegalovirus; CRF = chronic 
renal failure; GI = gastrointestinal; AMI = acute myocardial infarction.
1. Introduction
Since Hedner et al’s introduction of recombinant 
activated factor VII (rFVIIa) in 1988 [1], it has been 
observed that high doses of rFVIIa can dramatically 
stop bleeding in hemophilic patients with inhibitors 
[2,3], acquired hemophilia [4], congenital factor VII 
deficiency [5], and even in patients with Glanzmann’s 
thrombasthenia [6]. In contrast to the conventional 
concept of normal hemostasis, in which platelets 
and plasma proteins act on different pathways, the 
newly developed cell-base model of coagulation sug-
gests that initiation of a coagulation cascade starts 
from the binding of factor VIIa to tissue factor (TF) 
[7,8]. Initially, a small amount of thrombin is formed 
through the activation of factor X by TF-VIIa com plex. 
Although not sufficient to form a fibrin clot, this 
small concentration of thrombin further activates 
fac tors V, VIII, XI and, most importantly, platelets. 
Secondly, on the surface of activated platelets, the 
TF-VIIa complex activates factor IX, which in asso-
ciation with the activated forms of factors VIII, X and 
V, generates adequate amounts of thrombin, which 
subsequently change soluble fibrinogen to insoluble 
fibrin clots. It has been shown that administration of 
a supraphysiological high dose of rFVIIa can act by 
bypassing the factor VIII/IX pathway to create faster 
and much higher thrombin generation on the sur-
face of activated platelets that adhere to the site of 
injury. This TF-independent bypassing mechanism is 
able to mount a robust hemostasis effect in hemo-
philic patients with inhibitors or other coagulopathy- 
related hemorrhages.
In recent years, there has been increasing interest 
in the use of rFVIIa to treat bleeding in non-hemophilic 
patients [9]. Some reports have been published that 
record the use of rFVIIa in patients with major bleed-
ing where there is no pre-existing inherited bleeding 
disorder [10–14]. Here, we present our experience 
with using rFVIIa to treat four patients with no con-
genital bleeding disorder who presented with clinically 
uncontrolled hemorrhage.
2. Patients and methods
There were two female and two male patients, aged 
33–94 years, with life-threatening bleeding and dif -
ferent underlying diseases other than hemophilia or 
other congenital coagulation disorders. Recombinant 
factor VIIa (NovoSevenR; NovoNordisk A/S, Bagsvaerd, 
Denmark) was administered by intravenous bolus 
inj ection at least 2 hours apart. Clinical hemostatic 
res ponse was classified as effective, partially effective 
and ineffective as evaluated for hemophilic patients 
[3]. An effective response was defined as bleeding 
stopping within 8–14 hours of treatment. A partially 
eff ective response was defined as bleeding stopping 
or significant slowing of the hemorrhage after 14 
hours of treatment. No clinical hemostatic effect was 
defined as an ineffective response.
3. Results
The clinical manifestations and treatment outcomes 
for the four patients are summarized in Table 1 and 
described in detail below.
3.1. Case 1
An 84-year-old woman who had been generally 
healthy was found to have hypovolemic shock after an 
episode of massive coffee-ground vomiting and tarry 
stool passage. Endoscopic examination disclosed an 
active gastric ulcer with bleeding. Laboratory data 
showed white blood cell count (WBC) 7300/μL, hemo-
globin 6.0 g/dL, and platelet count 21,000/μL. The 
drop in hemoglobin and platelet count was initially 
thought to be due to bleeding. However, the platelet 
count remained at low levels (34,000–42,000/μL) even 
after endoscopic hemostatic procedures and plate-
let transfusion. A bone marrow examination was per-
formed and myelodysplastic syndrome was con firmed 
based on morphological and flow cytometric analysis.
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Two weeks later, her condition was complicated 
by hospital-acquired pneumonia, which resulted in 
respiratory failure. The pneumonia progressed to 
acute respiratory distress syndrome (ARDS) and 
caused further reduction in platelet count to around 
9000–20,000/μL. In addition, bloody oozing from 
multiple sites was noted, including the endotracheal 
tube, oral mucosa, venous puncture sites and inter-
mittently recurring tarry stools which were refrac-
tory to platelet transfusion and medical treatment. 
Furthermore, barotrauma occurred due to poor com-
pliance of the lung condition, resulting in right side 
tension pneumothorax that required emergent chest 
tube drainage. Laboratory data showed WBC 4500/μL, 
hemoglobin 7.5 g/dL, platelet count 13,000/μL, pro-
thrombin time (PT) 11.7 seconds (normal range, 
9.9–11.6 seconds), and activated partial thrombo-
plastin time (aPTT) 35.7 sec onds (normal range, 
23.9–34.9 seconds).
Fearing uncontrolled bleeding would result from 
the invasive procedure of chest tube insertion, one 
dose of rFVIIa 90 μg/kg was given. Fifteen minutes 
later, the PT had shortened to 8.2 seconds and aPTT 
to 32.9 seconds. A chest tube was then smoothly 
in serted without any bleeding. Meanwhile, her plate-
let count rose to 79,000/μL for the first time after a 
trans fusion, a response not previously in evidence 
before rFVIIa administration. The hemorrhage from 
multiple sites stopped as well. A second half-dose 
of rFVIIa, of 45 μg/kg, was given the next day before 
a tra cheostomy because of prolonged intubation. 
Again, no bleeding was evident during and after 
this invasive procedure. No other adverse effect 
was seen after rFVIIa injection. Unfortunately, she 
passed away from worsening pneumonia with septic 
shock.
3.2. Case 2
The condition of a 33-year-old man with chronic mye-
loid leukemia was complicated by extensive chronic 
graft-versus-host disease (GVHD) after receiving alloge-
neic bone marrow transplantation from his younger sis-
ter. The GVHD flared up, necessita ting treatment with 
aggressive immunosuppressing agents. Un fortunately, 
his condition was further complicated by cytomegalo-
virus (CMV) pneumonia with respiratory failure. Stand-
ard antiviral agents, ganciclovir and CMV-intravenous 
immunoglobulin, were given. However, his pneumo-
nia soon deteriorated into ARDS with progressively 
decreasing oxygenation. He began to have pulmonary 
hemorrhage with profuse blood-tinged secretions via 
the endotracheal tube. The bleeding was thought 
to be due to serious pulmonary damage from ARDS. 
Meanwhile, platelet count was kept at 53,000/μL, 
PT at 9.8 seconds, and aPTT at 25.6 seconds. The 
oxygenation was further compromised with a drop 
in oxygen saturation (SaO2) to 80% even on the max-
imum setting of the ventilator.
In an attempt to save his life, one dose of rFVIIa 
80 μg/kg was tried immediately. Soon after the 
injection of rFVIIa, bleeding from the endotracheal 
tube subsided and his SaO2 went up dramatically 
to 92% 30 minutes later. The SaO2 stayed above 
95% for an additional 12 hours, accompanied by a 
decrease in the secretion of blood-tinged sputum. 
Unfortunately, his SaO2 dropped again down to 80%. 
Although not much blood-tinged secretion was in evi-
dence this time, a second dose of rFVIIa 100 μg/kg 
was tried, but had no effect this time. The patient 
passed away because of severe pulmonary damage 
from ARDS.
3.3. Case 3
A 94-year-old woman with a history of chronic renal 
insufficiency for 9 years was noted to have massive 
tarry-bloody stool passage, which caused hypovolemic 
shock. Aggressive transfusion of blood components 
was immediately provided and a thorough endo scopic 
study to search for any bleeder in the gastrointes-
tinal tract was recommended. However, her family 
refused any invasive procedure including endoscopy 
or angiography because of her advanced age. Initial 
laboratory data showed WBC 13,600/μL, hemoglobin 
6.4 g/dL, platelet count 245,000/μL, PT 10.7 seconds, 
aPTT 24.2 seconds, blood urea nitrogen 55 mg/dL, 
and creatinine 4.9 mg/dL. In addition to blood com-
ponents transfusion including whole blood, packed 
red cells and fresh frozen plasma, tranexamic acid 
and desmopressin were given to help control bleed-
ing as well. However, the bleeding persisted with 
blood pressure dropping to 77/52 mmHg, hemo-
globin to 5.9 g/dL, and platelet count to 78,000/μL, 
while PT went up to 24.1 seconds and aPTT to 47.8 
seconds. Furthermore, pulmonary edema developed 
due to volume overload after aggressive transfusion. 
So, one dose of rFVIIa in a 100 μg/kg intravenous 
bolus injection was tried. Dramatically, her bleeding 
stopped 2 hours later, with PT down to 8.4 seconds 
and aPTT to 31.5 seconds. However, tarry-bloody 
stool passage recurred 24 hours later. As her fam-
ily continued to refuse endoscopic or angiographic 
studies, repeated doses of rFVIIa 100 μg/kg were 
given at intervals of 2–4 hours. The gastrointesti-
nal bleed ing finally stopped after administration of 
an additional six doses of rFVIIa. Her hemodynam-
ics stabilized with no more tarry stool passage. 
Unfortunately, acute myocardial infarction occurred 
15 hours after the last dose of rFVIIa. Although no 
more bleeding was found thereafter, she passed away 
due to cardiogenic shock.
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3.4. Case 4
A 46-year-old man diagnosed with oral squamous 
cell carcinoma with metastases affecting multiple 
bones and the left axillary lymph node had received 
a course of systemic chemotherapy of cisplatin plus 
96-hour 5-fluorouracil infusion. Although the tumor 
shrank, 18 days later, his condition was complicated 
by an episode of massive bloody stool passage which 
immediately put him into hypovolemic shock. Both 
esophagogastroduodenoscopy and colonoscopy dis-
closed no causative bleeder. Laboratory data showed 
WBC 11,400/μL, hemoglobin 7.5 g/dL, platelet count 
83,000/μL, PT 13.1 seconds and aPTT 43.7 seconds. 
The prolongation of aPTT was probably due to loss of 
plasma proteins from bleeding, since his baseline PT 
and aPTT were in the normal range.
Transfusion with multiple blood components was 
initially provided, and his aPTT returned to within 
normal limits. The bleeding recurred the next day. 
Angiography was performed but no bleeder was found. 
Once again, massive bloody stool was noted on the 
third day. Angiography was immediately performed, 
showing hyperemic distribution of blood vessels orig-
inating from the superior mesenteric artery, but still 
a definite bleeder could not be identified. Because 
no coagulopathy was found in this patient, two doses 
of rFVIIa 85 μg/kg were administrated at 2-hour inter-
vals. The initial response was good, stabilizing hemo-
dynamics and no further bloody passage was seen. 
Unfortunately, 4 hours after the first dose of rFVIIa, 
massive bleeding recurred. The third angiography dis-
closed two active bleeders on the branches of the supe-
rior mesenteric artery. Embolization was performed 
smoothly, stopping the hemorrhage. However, sud-
den onset of bleeding occurred again the next day, 
which caused a standstill, and it was too late to per-
form any invasive hemostatic procedure.
4. Discussion
We report a series of four patients who were treated 
with rFVIIa for uncontrolled, life-threatening hemor-
rhage in the absence of an inherited bleeding dis-
order. The clinical responses varied. Sustained and 
effective hemostasis was achieved in one patient. Two 
patients showed a partially effective response and the 
last patient did not respond to treatment. Although 
rFVIIa has shown excellent hemostatic effects for treat-
ing bleeding in hemophilia with inhibitors, its role as 
a universal hemostatic agent remains debatable and 
experience using rFVIIa outside of the hemophilia 
population are somewhat limited. Numerous case 
reports have been published in the past [10–14]. All 
four patients had bleeding that could not be stopped 
initially by medical treatment, including massive 
transfusion of blood components, use of antifibri-
nolytic agents and even repeated surgery to ligate 
the bleeding vessels. Hemostasis was successfully 
achieved by injection of rFVIIa 90 μg/kg of variable 
doses. Subsequently, several retrospective studies 
including more patients have been published. For 
example, O’Connell et al reported that in a study 
with a total of 40 patients who received rFVIIa for 
uncontrolled bleeding from different causes, bleed-
ing stopped or decreased in 80% [15]. Other reports 
described potential response for upper gastrointes-
tinal bleeding [16], postvascular surgery [17] and 
postpartum hemorrhage [18].
To date, several randomized clinical trials using 
rFVIIa for non-hemophilic bleeding have been com-
pleted. In 36 patients who underwent retropubic 
prostatectomy, Friederich et al reported that a single 
preoperative dose of rFVIIa, either 20 μg/kg or 40 μg/
kg, reduced blood loss by 50–60% [19]. Mayer et al 
conducted a randomized trial of 399 patients with 
spontaneous intracerebral hemorrhage that showed 
significant reduction in the growth of hematoma, mor-
tality and improved functional outcomes for the rFVIIa 
treatment groups (receiving one dose of rFVIIa 40 μg/
kg, one dose of 80 μg/kg or one dose of 160 μg/kg vs. 
placebo) [20]. Significant reduction in need for blood 
components transfusion has also been noted in treat-
ment for blunt or penetrating traumatic hemorrhage 
after using rFVIIa as an adjuvant therapy [21]. In con-
trast, in 245 patients with liver cirrhosis and either 
variceal or non-variceal upper gastrointestinal bleed-
ing, Bosch et al failed to show better hemostasis in the 
rFVIIa treatment group [22], but the study did reveal 
some improvement in the control of variceal bleeding 
in patients with Child-Pugh B and C liver function.
Moreover, rFVIIa may also help control bleeding in 
patients with thrombocytopenia. It is well known that 
platelets play an important role in hemostasis, both 
in the formation of the primary hemostatic platelet 
plug and through generation of procoagulant activity, 
leading to stabilization of the plug by fibrin. The latter 
effect is especially augmented by rFVIIa, since rFVIIa 
can activate platelets and recruit greater numbers 
of activated platelets to the site of vascular injury 
than would normally occur in thrombocytopenia [7,8]. 
In one study, 74 patients with thrombocytopenia 
were infused with rFVIIa [23]. A reduction in bleed-
ing time occurred in 52% of evaluable treatment epi-
sodes. In another study, rFVIIa was used to manage 
hemorrhage in 24 patients with thrombocytopenia 
associated with hematologic malignancies. Bleeding 
stopped in 46% and markedly decreased in 33% of 
patients, respectively [24]. Our first patient with mye-
l odysplastic syndrome and pneumonia whose con-
dition was complicated by severe thrombocytopenia 
and gastrointestinal bleeding showed an excellent 
response of hemostasis after rFVIIa injection.
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The optimal dosage of rFVIIa for the control of 
non-hemophilic bleeding remains to be established. 
Experience with hemophilic patients shows that to 
achieve maximum clinical hemostasis, the dosage of 
rFVIIa should be high enough to maintain a plasma 
level of factor VII activity (VII:C) of > 600%, correspond-
ing roughly to a dose of 90–120 μg/kg [25]. Currently, 
in patients with hemophilia A or B with inhibitors 
and acquired hemophilia, the recommended dos-
age of rFVIIa is 90 μg/kg at intervals of 2–3 hours 
[26]. Most published reports in the literature have 
applied a dosage range similar to that used for hemo-
philia [15,18,20,22–24], the majority using one to two 
doses. For massive traumatic hemorrhage, an Israeli 
group recommended an initial dosage of 120 μg/kg 
that may be followed by an additional dosage of 
100 μg/kg [27]. It seems some patients have an excel-
lent response to only one dose of rFVIIa but others may 
need more doses to control bleeding, as demonstrated 
by our cases. Although PT is universally shortened 
after a conventional single dose of rFVIIa, it remains 
an indirect measurement of thrombin generation 
and the shortening in PT may not reflect an adequate 
amount of thrombin production that allows clinical 
bleeding to continue. More recently, the application 
of clot waveform analysis and thrombin generation 
assays have provided more precise assessment of 
clotting function when monitoring rFVIIa treatment 
for hemophilia [28]. In addition, a higher dosage of 
rFVIIa may be needed for patients with inadequate 
thrombin generation in response to conventional dos-
age. Dosage up to 200 μg/kg have been tried in both 
hemophilic and non-hemophilic patients with good 
response [21,29]. However, the efficacy and safety 
of high-dose rFVIIa remains to be investigated in 
well-designed trials.
With over a decade of use, rFVIIa has generally 
been well tolerated by patients with hemophilia with 
inhibitors. Although serious adverse events, mainly 
thromboembolic effects, may occur in approxi-
mately 1% of patients [30], most of the thrombotic 
events occurred in patients with predisposing factors. 
However, in the trial using rFVIIa for acute intracere-
bral hemorrhage, Mayer et al demonstrated a trend 
toward more thromboembolic events than in the pla-
cebo group, 7% vs. 2% (p = 0.12) [20]. In our series, 
Case 3 died of acute myocardial infarction after seven 
doses of rFVIIa injection, despite slowing intractable 
gastrointestinal bleeding. Her very advanced age 
and/or possible underlying atherosclerosis may have 
played a role in the development of myocardial infarc-
tion. However, the safety of rFVIIa for treating non-
hemophilic patients, especially elderly ones, needs 
further clarification.
In conclusion, there is a clinical need for one or 
more new hemostatic agents to treat bleeding that 
cannot be controlled by surgical intervention, local 
hemostatic procedures, and transfusion of blood 
products. Based on our experience and previously 
reported series, rFVIIa may be used as a last attempt 
to stop life-threatening hemorrhage. However, clinical 
hemostatic effects that could not be translated into 
a survival benefit among our cases calls for further 
research, especially with regard to appropriate timing 
of its clinical use. Its wide use and safety concerns 
warrant further clinical study.
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